Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK92MI + HN3
- Development stage
- Preclinical
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NK92MI + HN3 is a combination cell therapy consisting of genetically engineered NK92MI cells expressing a third-generation chimeric antigen receptor (CAR) constructed using HN3, a human single-domain antibody targeting a conformational epitope on the core protein of glypican-3 (GPC3). NK92MI is an IL-2-independent natural killer cell line capable of indefinite expansion. The CAR construct incorporates signaling domains CD28, 4-1BB ligand, and CD3 zeta, designed to enhance cytotoxicity. The principal indication is for **hepatocellular carcinoma (HCC)**, for which GPC3 is highly expressed. NK92MI/HN3 shows significant anti-tumor activity against GPC3-positive HCC cells in vitro and inhibits tumor growth in xenograft mouse models. Its cytotoxicity is influenced by GPC3 isoform expression. Primary mechanism involves targeted lysis of GPC3-expressing tumor cells via CAR-mediated recognition and NK effector functions, with increased production of IFN-γ and expression of CD107a upon engagement.
- Brand names
- NK92MI/HN3
- Other names
- NK92MI + HN3NK92MI/HN3
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on NK92MI + HN3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK92MI + HN3.